Clinical research is for everyone

Inclusion is a major value for the EMN, particularly when it comes to clinical trials. The myeloma community is in fact highly heterogeneous and the EMN strongly believes that the same high-quality treatments should be offered to any patients, regardless of their gender, race, ethnicity, sexual orientation, disability, religion, age, cultural backgrounds, life experiences, thoughts, and ideas. We are extremely grateful for the fundamental role our patients play in the EMN clinical studies, and the contribution of each one of them is equally recognized and appreciated.

Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for Treatment of Myeloma Patients Presenting with Extramedullary Disease. The Antares Study
Phase 2 study of daratumumab monotherapy in previously untreated patients with stage 3B light chain (AL) amyloidosis The Alcaeus Study
A retrospective observational multicenter study on the management and outcome of patients with systemic AL amyloidosis in Europe